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Gastric output of pancreatic secretory trypsin
inhibitor is increased by misoprostol
R J Playford, J J Batten, T C Freeman, K Beardshall, D A Vesey, G C Fenn, J H Baron, J Calam
Abstract
Pancreatic secretory trypsin inhibitor (PSTI)
is a potent protease inhibitor that also has
growth promoting activity. It has recently been
identified in the foveolar cells of the stomach,
which secrete mucus. We examined the effects
of the prostaglandin E1 analogue misoprostol
on gastric PSTI output. Seven normal
volunteers took part. An initial period ofgastric
aspiration was followed by four 40 minute
periods of gastric perfusion at 5 ml/minute of:
0-14 molll saline, 0.17 mmol/l bicarbonate,
bicarbonate with misoprostol 400 rig, and then
bicarbonate again. All perfusates contained
polyethylene glycol 4000 as a marker. Miso-
prostol increased median gastric secretion of
PSTI from 11 to 33 ig/hour (p<005), pro-
ducing concentrations in gastric juice six times
higher than those found in jejunal juice and
about 1/30 of the values seen in pancreatic
juice. Median mucus secretion increased to a
lesser extent from 29 to 38 mg/hour during
misoprostol. There was no change in intra-
gastric concentrations of protein or of
epidermal growth factor during infusion of
misoprostol. Infusion of pentagastrin (6 iglkg/
hour) had no effect on gastric secretion of
mucus, PSTI, or protein. Human gastric
mucus was degraded on incubation with trypsin
in vitro and this was prevented by the addition
of PSTI. These results suggest that gastric
PSTI may protect the gastric mucus layer
against refluxed pancreatic proteases.
Increased output of PSTI during microprostol
may contribute to the protective effect of this
drug.
Gastroenterology Unit,
Department of Medicine,
Royal Postgraduate
Medical School, London
R J Playford
J J Batten
T C Freeman
K Beardshall
D A Vesey
G C Fenn
J Calam
GD Searle and Co Ltd,
High Wycombe,
Buckinghamshire
G C Fenn
Correspondence to:
Dr J Calam, Gastroenterology
Unit, Department of
Medicine, Royal Postgraduate
Medical School, Du Cane
Road, London W12 ONN.
Accepted for publication
14 December 1990
Pancreatic secretory trypsin inhibitor (PSTI) is a
potent inhibitor of trypsin and chymotrypsin'
that has recently been found in the foveolar cells
of the stomach as well as in the pancreas.2 3 The
foveolar cells also secrete mucus,4 which helps to
create the protective gastric mucus layer.5 We
therefore speculated that PSTI may protect the
gastric mucus layer from damage by pancreatic
proteases that reflux into the stomach in normal
people and, to a greater extent, in diseases
including chronic gastric ulcer.6 Because the
prostaglandin E1 analogue misoprostol heals
gastric ulcers7 and increases the concentration of
mucus in gastric juice,8 we examined its effect on
the gastric output of PSTI.
When considering the proposed protective
effect of PSTI against pancreatic enzymes, it is
important to note that both PSTI and trypsin are
digested by pepsin, but only at a low pH.9'0
Pepsin, however, is inactive against trypsin and
PSTI at pH values >4'° - values that occur
normally within the mucus layer5 and in the
lumen when acid secretion is reduced by disease
or drugs," 12 buffered by food, or neutralised by
refluxed duodenal juice. 3We therefore measured
gastric PSTI both before and during intragastric
neutralisation with bicarbonate. Epidermal
growth factor was measured as a control protein
of similar size to PSTI, present in gastric juice,
but principally of salivary origin.'4
The effect of pentagastrin on gastric secretion
of mucus was also investigated because penta-
gastrin has been reported to increase mucus
secretion in the cat,'5 but to decrease it in man. 16
Subjects and methods
ETHICS
The study protocols were approved by the local
ethics committee and all patients and volunteers
gave informed consent.
EFFECT OF GASTRIC PERFUSION WITH SALINE,
BICARBONATE, AND MISOPROSTOL
Dose finding study
In a preliminary experiment, a normal subject (a
man, aged 42 years) took part in an extended
study using methods described below. He
underwent five 40 minute periods of perfusion
with 0 17 mmol/l bicarbonate to which 0, 0.2, 1,
and 2 [ig/ml misoprostol were added (giving
doses of 0, 40, 200, and 400 [ig over the relevant
40 minute periods).
The main study
Seven subjects took part in this study. After an
overnight fast, a double lumen nasogastric tube
was placed for continuous aspiration from the
gastric antrum with infusion 20 cm proximally.
Each study had five stages of 40 minutes each:
aspiration only, perfusion with 0a 14 mol/l saline,
perfusion with 0.17 mol/l sodium bicarbonate,
bicarbonate with 400 [ig misoprostol (2 ,ug/ml),
and bicarbonate alone (Fig 1). Four subjects had
a repeat study one week later with two stages of
40 minutes each - aspiration only followed by
saline perfusion and then an 80 minute perfusion
with 0. 17 mol/l sodium bicarbonate (Fig 1). The
perfusion rate was 5 ml/minute and all perfusates
contained 5 g/l of polyethylene glycol 4000 and
0-2% ethanol, which was required to dissolve the
misoprostol. Aspirates were continuously
collected on ice and were stored in 10 minute
batches, mixed thoroughly, and samples titrated
to the pH of the perfusate or, in the case of saline
perfusion, to pH 7.0. Neutralised samples for
radioimmunoassay were frozen and stored at
-200C.
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Figure 1: Gastric secretion of
pancreatic secretory trypsin
inhibitor (PSTI) in seven
healthy volunteers (open
circles). The study comprised
five 40 minute stages: simple
aspiration, then gastric
perfusion with; 0.14 molll
saline, 0 17 molll sodium
bicarbonate, bicarbonate
with 400 [og ofmisoprostol(MISO), then bicarbonate
alone again. Intragastric
perfusion with 400 [og
misoprostol caused a
significant increase in output
(p<0 05) ofPSTI which
was maintained throughout
thefinal bicarbonate period.
The closed circles indicate
results in four subjects in
whom bicarbonate was
continued without
misoprostol.
+ misoprostol
0 80 120 160
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To assess possible gastric damage resulting
from the procedure or the drug, one volunteer
was examined by fiberoptic endoscopy 30
minutes after the end of the study.
EFFECT OF PENTAGASTRIN
The effect of pentagastrin was studied similarly
in six subjects (five men and one woman, age
range 21-45 years). To neutralise stimulated
acid, 0-17 mol/l sodium bicarbonate was perfused
intragastrically at 10 ml/minute for 180 minutes.
Pentagastrin, 6 [tg/kg/hour, was infused into a
forearm vein from 60-120 minutes.
COLLECTION OF NORMAL FASTING DUODENAL
JUICE
Duodenal aspirates were obtained from four
fasted healthy men via a weighted single lumen
tube screened into the duodenojejunal junction.
Samples were analysed for bilirubin, protein,
trypsin, and PSTI.
analyser (Technical instruments Co) and
Technitron method number SM-0179887. All
samples were also analysed for trypsin using N -
Benzoyl -DL- Arginine p-Nitroanilide (BAPNA)
as substrate.2' The lower limits of detection for
bilirubin and trypsin were 2 [imol/l and 5 Rg/ml
respectively. Any samples containing detectable
bilirubin or trypsin were discarded.
EFFECT OF TRYPSIN ON HUMAN GASTRIC MUCUS
IN VITRO
Some 6 mg ofhuman gastric mucus glycoprotein,
derived from 10 ml of the gastric juice of a
healthy volunteer were incubated with 100 tg of
bovine trypsin (Sigma Type III) in a total volume
of 10 ml, in 0 1 mol/l TRIS buffer pH 7.8 with
and without 26 [ig of human PSTI, an amount
equimolar with the amount of trypsin added.
After incubation for 24 hours at 37°C, the mucus
was analysed by gel filtration using a 16x900
mm Sephacryl S-500 column eluted with 0.05
mmol/l NaCl at 21C. Eluates were analysed for
mucus carbohydrate as described above.
CALCULATIONS AND STATISTIC ANALYSIS
For the study of the effects of misoprostol, all
results were compared with those obtained
during the first period of bicarbonate perfusion
and analysed using the Wilcoxon rank paired
test. Secretion rates were determined using
polyethylene glycol dilution and polyethylene
glycol recovery was used to correct for pyloric
losses. The mean of the last two time points of
each stage (final 20 minutes) for each individual
subject was calculated as we considered that
plateau values had been reached. The median
(range) of the values from all the subjects are
shown in the Table and the median of each
individual 10 minute period for PSTI output is
shown in Figure 1. Because acid, pepsin,
epidermal growth factor, carbohydrate, and
PSTI secretion were not normally distributed,
results are expressed as median (range) and
p<005 was taken to be statistically significant.
Results
EFFECTS OF MISOPROSTOL
LABORATORY ANALYSES
PSTI was measured using antiserum T4 as
described previously,'0 protein was analysed
using a modified method of Lowery,'7 and
mucus carbohydrate analyses were by the phenol
sulphuric method.8 Results were analysed using
a galactose standard curve at an absorbance of
490 nm. Epidermal growth factor was measured
by the specific radioimmunoassay described by
Savage.'9 We examined the cross reactivity of
transforming growth factor a in this assay.
Polyethylene glyclol was measured in samples by
a turbidometric method.20 Gastric acid secretion
was measured by back titrating aspirates to their
original pH, which was 8-3 for bicarbonate
perfusion (or pH 7 0 in the case of simple
aspiration or saline perfusion) using a Metrohm
automatic titrator (Switzerland). All aspirates
were analysed for bilirubin using an RA-1000
Dosefinding study
In the single subject who received increasing
doses of misoprostol, the measured outputs of
PSTI were: 18, 26, 35, and 31 pg/hour after
infusion of 0, 0-2, 1, and 2 [ig/ml of misoprostol
providing 0, 40, 200, and 400 jig over the 40
minute periods respectively. These results
showed that the output of PSTI increased in a
dose dependant manner with maximal stimu-
lation being reached during the 200 pg miso-
prostol per 40 minute dose (1 pg/ml). The 40 ,ug
misoprostol per 40 minute dose (0 2 ptg/ml)
increased PSTI output by 35% but did not affect
the total volume of secretion, protein concen-
tration, or acid output. Both the 200 and 400 [ig
per 40 minute doses of misoprostol were associ-
ated with complete acid suppression.
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Effect of400 gg misoprostal on gastric luminal pancreatic secretory trypsin inhibitor (PSTI),
mucus, protein, epidertnal growthfactor (EGF), acid output, and volume ofsecretion in seven
healthy volunteers, (values, median (range))
Perfusate
Initial Misoprostol+ Final
bicarbonate bicarbonate bicarbonate
PSTI secretion ([tg/hour) 11 (8-45) 33 (15-85)* 32 (23-85)*
PSTI concentration (ng/ml) 127 (75-222) 386 (173-599)* 388 (245-607)*
Mucus secretion (mg/hour) 29(19-39) 38(25-49) 37(25-58)
Mucus concentration ([tg/ml) 245 (222-399) 372 (257-661) 432 (250-664)*
Protein secretion (mg/ml) 395 (207-495) 324(252-512) 340 (237-354)
Protein concentration (mg/ml) 4.0 (2.3-4.8) 2-8 (210-5.5) 3-1 (2-1-5-0)
EGF secretion (pmollhour) 5-4 (1-7-11i5) 6-1 (2-3-11-5) 6-4 (1-3-12-3)
EGF concentration (fmol/ml) 65(28-182) 44(24-196) 59(10-197)
Acid secretion (meq/hour) 8-8 (0-5-14-5) -0-6 (-1-5-12)* -0.4 (-4.1-0)*
Volume of secretion (ml/hour) 126(57-142) 123(50-180) 105 (69-141)
The main study
Eighteen ofthe 140 sampleswere rejected because
they contained bilirubin or trypsin; four from
each of the aspiration, saline perfusion, and
initial bicarbonate periods and two from each of
the bicarbonate plus misoprostol and final
bicarbonate periods.
Measured gastric output of PSTI was mean
(range) 2 (1-3) ,tg/hour during simple aspiration,
4 (3-5) FIgIhour during perfusion with saline,
and rose to a plateau of 11 (8-45) mg/hour during
the first bicarbonate period. Gastric secretion of
PSTI remained at 11 (7-21) pg/hour (NS) when
bicarbonate perfusion was continued without
misoprostol for a further 40 minutes in four
subjects. During perfusion with misoprostol,
gastric secretion of PSTI rose to 33 (15-85) [ig/
hour (p<0 05). The maximal secretion rate was
achieved after 200 ,ug of misoprostol had been
given. Calculated concentrations of PSTI in
gastric juice also rose significantly from 127 (75-
222) ng/ml to 386 (173-599) ng/ml (p<005)
during misoprostol perfusion. The changes in
PSTI secretion and concentration persisted
throughout the second control period.
Gastric mucus secretion rose from 29 (19-39)
mg/hour to 38 (25-49) mg/hour after misoprostol
(NS). An increase in the concentrations ofmucus
in gastric juice became significant during the
second control period: 432 (250-664) [ig/ml
compared with 245 (222-399) pg/ml (p<005)
before misoprostol.
Misoprostol also reduced acid secretion from
8-8 (0 5-14 5) mEq/hour to -0-6 (-1 5-12)
mEq/hour during misoprostol, and -0.4
(-4. 1-0) mEq/hour after misoprostol (p<0 05).
The pH ofgastric aspirates was 1 3-2-8 during
basal aspiration, 2 1-5.0 during perfusion with
saline, 7.5-8.2 during the first bicarbonate
period, 7.5-8 4 during misoprostol, and 8.3-8-7
during the final bicarbonate period.
There was no significant change in the total
volume of secretion, measured by dilution of
polyethylene glycol, or the rate of secretion of
total protein or epidermal growth factor during
or after misoprostol. Transforming growth
factor a did not inhibit the binding of epidermal
growth factor tracer to the antiserum in the
epidermal growth factor radioimmunoassay. The
ratio of bound: free epidermal growth factor
tracer was 0-6 in the absence of added protein
(final antibody concentration 1/80 000). Binding
was 50% inhibited by 15 fmol of epidermal
growth factor/tube, but the ratio was >0 58 with
0.3
0.2
0.1
20 40 60 80
Fraction no
Figure 2: Damage to gastric mucus assessed by gel
filtration. This separates molecules according to size, the
largest elutingfirst. Normal mucus elutes as an early
single peak indicated by an arrow in the void volume.
Total volume indicates column's total bed volume. (A) After
incubation with trypsin, the mucus elutes later indicating
breakdown of its structure to smallerfragments. (B) The
presence ofpancreatic secretory trypsin inhibitor in the
incubation medium prevented this destruction ofmucus.
all concentrations of transforming growth factor
a up to 150 pmol/tube.
The subject who underwent endoscopy after
the procedure had normal mucosa - both macro-
scopically and microscopically.
EFFECT OF PENTAGASTRIN
Pentagastrin had no apparent effect on gastric
secretion of PSTI or mucus. Rates of PSTI
output were 12 (7-19), 15 (7-26), and 10 (5-14)
p.g/hour, and rates of mucus output were 32
(28-40), 31 (25-36), and 29 (24-33) mg/hour
before, during, and after pentagastrin respec-
tively. The pH of the aspirates was never less
than 7-2 during the study.
EFFECT OF TRYPSIN ON HUMAN GASTRIC MUCUS IN
VITRO
After incubation of gastric mucus with trypsin,
mucus carbohydrate eluted in three peaks: 20%
eluted in the void volume (Vo, Kav= 1), the
remainder eluted later, principally in two peaks
with 35% at an elution coefficient (Kav)=0.3 and
0
0.3
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(t
0
U)en
0.2
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0.0
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43% at Kav=0-89, indicating breakdown of
mucus glycoprotein to smaller forms (Fig 2A). In
the presence of PSTI, however, 90% of mucus
carbohydrate eluted at Vo, the characteristic
position of native gastric mucus glycoprotein
(Fig 2B).
ANALYSIS OF DUODENAL JUICE
Median (range) concentrations in duodenal
aspirates were PSTI, 30 (0-40) ng/ml; trypsin,
195 (150-290) [ig/ml; protein, 28 (18-57) Rg/
ml; and bilirubin, 276 (9-406) Rmol/l. The
concentrations of PSTI were 0 1 mg (0-0 2)
expressed per 100 mg of protein in duodenal
juice.
Discussion
These studies show the first time that a thera-
peutic dose of the synthetic prostaglandin El
derivative misoprostol increases gastric output of
PSTI, and that PSTI can protect gastric mucus
from damage by trypsin.
The protocol was based on knowledge of the
nature of PSTI. Firstly, PSTI is destroyed by
pepsin at pH <4,10 so bicarbonate was used to
keep the intragastric pH neutral during the last
three test periods. The effect ofthis was tested by
comparing measured PSTI output during
administration of saline v bicarbonate. Secondly
gastric perfusion might 'wash' PSTI out of the
mucus layer. Therefore the stomach was perfused
at a constant rate during the last four test
periods. Also at acid pH, increased volume flow
might decrease peptic hydrolysis by diminishing
the time between its secretion and collection. To
examine this we compared measured output
between simple aspiration and saline perfusion.
The results that we obtained are consistent with
these ideas (Fig 1). There was a small transient
rise in measured PSTI output during saline
perfusion v simple aspiration, a further signifi-
cant rise when the perfusate was changed from
saline to bicarbonate and a more substantial rise
on the addition of misoprostol to bicarbonate.
The latter increase did not occur when miso-
prostol was omitted during this time period in
four subjects, indicating that the response was
to misoprostol rather than to prolonged perfu-
sion.
The prostaglandin El analogue (CL115,574,
Lederle, NY, USA) which resembles miso-
prostol, significantly increased gastric mucus
secretion in man and other animals.22 In our
study, however, as in that of Wilson et al who
also used misoprostol,8 there was a rise in mucus
secretion that was not statistically significant.
However in both studies the intragastric mucus
concentration rose significantly, partly as a result
of reduced secretion of water.
The rise in gastric PSTI output was specific
because protein output did not change. The
PSTI output rose more than mucus secretion,
even though PSTI is derived from foveolar cells
which secrete mucus. This may reflect selective
stimulation of PSTI secretion or a difference
between the recovery ofPSTI and mucus.
It is not clear whether PSTI, with a molecular
weight (MW) of 6000, diffuses freely though the
mucus layer or remains concentrated within it. A
molecule of MW 1500 diffused freely whereas
one of MW 17000 did not.23 The mucus layer
probably does retard the diffusion of trypsin
which has aMW 23 000, so interactions between
PSTI and trypsin probably occur at the luminal
surface of the mucus layer.
PSTI probably protects the stomach from
pancreatic proteases under conditions and in
locations where the pH is high, so that both the
PSTI and trypsin are active and not digested by
pepsin." Gastric PSTI is most abundant in the
antrum,3 which may be exposed to the highest
concentrations of trypsin, while neutralised by
refluxed duodenal contents. PSTI seems to be
the only trypsin inhibitor in human gastric juice.
Its concentration in gastric juice was about
130 ng/ml during gastric neutralisation and about
350 ng/ml after misoprostol compared with only
about 30 ng/ml in normal duodenal juice. The
low concentration in duodenal juice probably
reflects the hydrolysis of gastric and pancreatic
PSTI by the excess of pancreatic proteases
present.
The gastric mucus layer is believed to protect
the underlying epithelium by forming a diffusion
barrier that allows secreted bicarbonate to keep
the surface of the epithelial cells at a neutral pH,'
as well as by protecting the mucosa from
mechanical trauma by food. In patients with
gastric ulcers, the mucus layer is abnormal,
microscopically24 and biochemically, with an
increased proportion of low molecular weight
forms,25 suggesting proteolytic destruction.
These patients tend to have reduced secretion of
pepsin26 but increased duodenogastric reflux of
trypsin,'3 whichwe have shown produces changes
in mucus very similar to those seen in gastric
ulcer patients.25 PSTI greatly reduced this effect
of trypsin, so stimulation of PSTI secretion by
misoprostol may contribute to the therapeutic
effect of this drug. However, misoprostol does
stimulate other protective mechanisms and
duodenal juice contains other substances such as
bile salts that can damage the gastric mucus
layer. Prokinetic drugs that diminish duodeno-
gastric reflux27 may be beneficial in gastric ulcer
disease.
The concentrations ofepidermal growth factor
measured in gastric juice in the present study are
similar to those obtained by Konturek et al.'4
Misoprostol did not affect intragastric epidermal
growth factor, which is chiefly of salivary origin.
In our study, as in that of Wilson et all
misoprostol more or less abolished basal gastric
acid secretion. Negative values may have been
the result of misoprostol stimulated bicarbonate
secretion28 that may reduce the destruction of
PSTI by acid pepsin in a non-neutralised
stomach. The effects of misoprostol on our
volunteers persisted for at least 40 minutes after
the end of perfusion. Wilson et al showed that
misoprostol's effects on acid and mucus secretion
continue for at least 300 minutes after ingestion
of 800 ,ug.1 The result of the dose finding study,
taken with that of the main study, suggests that
the dose of misoprostol required to increase
PSTI output maximally is similar to that required
to inhibit acid secretion. Our dose finding study
in a single subject suggested, however, that
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40 [ig of misoprostal can increase PSTI output
without changing secretion.
Pentagastrin did not increase measured gastric
PSTI output in the present study, although the
same dose of pentagastrin did do so in our
previous study which was based on simple
aspiration of gastric juice."' The difference
probably reflects the different method used to
collect gastric juice, as discussed above. During
simple aspiration, pentagastrin stimulated
volume flow may have 'washed' PSTI out of the
mucus layer and reduced the duration of its
exposure to acid pepsin. Gastric perfusion with
bicarbonate may have reduced these effects in
the present study. An increase in lumenal mucus
during pentagastrin stimulation in the cat'" may
also have been caused by 'washout'.
PSTI stimulates the growth of some normal
and neoplastic cells,29 30 at concentrations similar
to those found in gastric juice.29 PSTI may
therefore affect gastric epithelial growth and play
a role in the stimulation ofepithelial proliferation
by misoprostol.3'
Bronchial, nasal, and seminal mucus secretions
all contain protease inhibitors,32 presumably to
prevent proteolytic digestion of the mucus.
Deficiency of a 1 antitrypsin in the respiratory
tract causes emphysema,33 probably through
uninhibited tissue proteases. We propose that
gastric PSTI may similarly protect the stomach.
Further studies are required to examine its
possible role in gastric disease.
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